Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/protocol/10.1007/978-1-4939-6481-9_5.

Title:
RNActive® Technology: Generation and Testing of Stable and Immunogenic mRNA Vaccines | SpringerLink
Description:
Developing effective mRNA vaccines poses certain challenges concerning mRNA stability and ability to induce sufficient immune stimulation and requires a specific panel of techniques for production and testing. Here, we describe the production of stabilized mRNA with...
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Education
  • Technology & Computing
  • Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

pubmed, mrna, article, vaccines, google, scholar, cas, rna, central, protocol, cancer, methods, privacy, cookies, content, information, publish, rnactive, heidenreich, doi, research, search, technology, schlake, vitro, vaccine, access, download, ingelheim, springer, usd, personal, data, log, journal, testing, rauch, lutz, kowalczyk, thomas, regina, book, chapter, kallen, biol, vaccination, selfadjuvanted, immunother, ther, cell,

Topics {✒️}

developing mrna-vaccine technologies month download article/chapter beta-globin untranslated regions thomas schlake & regina heidenreich messenger rna-based vaccines nucleotide-binding peptide protamine sequence-optimized mrna vaccines kallen k effective protein therapy provide antitumor activity nucleotide-based vaccines privacy choices/manage cookies fotin-mleczek device instant download rna-based treatments immunogenic mrna vaccines amplifying rna vaccines specific mrna vaccines disruptive vaccination technology heterologous mrna expression sequence-engineered mrna bmc cancer 14 adjuvanted mrna vaccination european economic area therapeutic antitumoral immunity highly efficient reprogramming german federal ministry author information authors paul-ehrlich-str editor information editors improving mrna stability synthetic modified mrna journal finder publish conditions privacy policy sindbis virus vector accepting optional cookies rna vaccines main content log protocol rauch protocol usd 49 mrna vaccines rnactive® technology rna biol 9 long rna check access ethics access protocol cite social media permissions reprints mrna sequence

Schema {🗺️}

ScholarlyArticle:
      headline:RNActive® Technology: Generation and Testing of Stable and Immunogenic mRNA Vaccines
      pageEnd:107
      pageStart:89
      image:https://media.springernature.com/w153/springer-static/cover/book/978-1-4939-6481-9.jpg
      genre:
         Springer Protocols
      isPartOf:
         name:RNA Vaccines
         isbn:
            978-1-4939-6481-9
            978-1-4939-6479-6
         type:Book
      publisher:
         name:Springer New York
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Susanne Rauch
            affiliation:
                  name:CureVac AG
                  address:
                     name:CureVac AG, Tübingen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Johannes Lutz
            affiliation:
                  name:CureVac AG
                  address:
                     name:CureVac AG, Tübingen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Aleksandra Kowalczyk
            affiliation:
                  name:CureVac AG
                  address:
                     name:CureVac AG, Tübingen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Thomas Schlake
            affiliation:
                  name:CureVac AG
                  address:
                     name:CureVac AG, Tübingen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Regina Heidenreich
            affiliation:
                  name:CureVac AG
                  address:
                     name:CureVac AG, Tübingen, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      keywords:mRNA vaccines, RNActive®, Protamine complexation, GC enrichment, Adjuvanticity, Stabilized mRNA
      description:Developing effective mRNA vaccines poses certain challenges concerning mRNA stability and ability to induce sufficient immune stimulation and requires a specific panel of techniques for production and testing. Here, we describe the production of stabilized mRNA with enhanced immunogenicity, generated using conventional nucleotides only, by introducing changes to the mRNA sequence and by complexation with the nucleotide-binding peptide protamine (RNActive® technology). Methods described here include the synthesis, purification, and protamine complexation of mRNA vaccines as well as a comprehensive panel of in vitro and in vivo methods for evaluation of vaccine quality and immunogenicity.
      datePublished:2017
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
      context:https://schema.org
Book:
      name:RNA Vaccines
      isbn:
         978-1-4939-6481-9
         978-1-4939-6479-6
Organization:
      name:Springer New York
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:CureVac AG
      address:
         name:CureVac AG, Tübingen, Germany
         type:PostalAddress
      name:CureVac AG
      address:
         name:CureVac AG, Tübingen, Germany
         type:PostalAddress
      name:CureVac AG
      address:
         name:CureVac AG, Tübingen, Germany
         type:PostalAddress
      name:CureVac AG
      address:
         name:CureVac AG, Tübingen, Germany
         type:PostalAddress
      name:CureVac AG
      address:
         name:CureVac AG, Tübingen, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Susanne Rauch
      affiliation:
            name:CureVac AG
            address:
               name:CureVac AG, Tübingen, Germany
               type:PostalAddress
            type:Organization
      name:Johannes Lutz
      affiliation:
            name:CureVac AG
            address:
               name:CureVac AG, Tübingen, Germany
               type:PostalAddress
            type:Organization
      name:Aleksandra Kowalczyk
      affiliation:
            name:CureVac AG
            address:
               name:CureVac AG, Tübingen, Germany
               type:PostalAddress
            type:Organization
      name:Thomas Schlake
      affiliation:
            name:CureVac AG
            address:
               name:CureVac AG, Tübingen, Germany
               type:PostalAddress
            type:Organization
      name:Regina Heidenreich
      affiliation:
            name:CureVac AG
            address:
               name:CureVac AG, Tübingen, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:CureVac AG, Tübingen, Germany
      name:CureVac AG, Tübingen, Germany
      name:CureVac AG, Tübingen, Germany
      name:CureVac AG, Tübingen, Germany
      name:CureVac AG, Tübingen, Germany
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(101)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js

CDN Services {📦}

  • Pbgrd

4.16s.